Welcome to the website of the New Diagnostics Working Group

The New Diagnostics Working Group (NDWG) is one of the seven working groups of the Stop TB Partnership. It supports the Partnership in its goal of eliminating tuberculosis (TB), in particular by promoting the development and evaluation of new TB diagnostic tools. The NDWG is a network of experts representing stakeholders from academia, NGOs, multilaterals and governmental institutions, TB high-burden countries, industry, and the patient community.


Joint FIND and NDWG symposium

11 October 2017, 13:00 - 17:00
Expo Guadalajara Convention Centre, Guadalajara, Mexico

This year, FIND and the New Diagnostics Working Group (NDWG) joined in convening partners and members at a symposium which was held on 11 October back-to-back with the 48th Union World Conference on Lung Health.

During the symposium, we provided an overview of the most recent advances in the global TB diagnostics pipeline and reviewed progress made in various areas to address diagnostic needs towards ending the TB epidemic. Sessions focused on the use of next-generation sequencing for surveillance, diagnosis and patient management, and on the development of new tests for latent TB infection to support TB elimination.

The event also involved a round table discussion around the challenges in molecular testing roll-out on a programmatic level. Panelists considered how the interpretation of genetic mutations can guide clinical decision for treatment and shared different perspectives about the prospects of scaling up molecular approaches in different settings.



New Diagnostics Working Group Annual Meeting

Wednesday, 26 October 2016, 9:00 - 12:30
Arena and Convention Centre, Liverpool, UK

The NDWG convened its Annual Meeting on 26 October 2016 at the 47th Union World Conference on Lung Health in Liverpool, UK.

NDWG Task Force members and partners reviewed progress in various areas of diagnostics R&D to support the targets of the End TB strategy and the Global Plan to End TB. Presentations covered newer understanding of LTBI diagnosis, as well as advanced drafts of the TPP for a test of progression of incipient TB and the Framework for evaluation of novel LTBI tests; the perspectives of next generation sequencing for detection of drug resistance in high TB burden countries; and a recent overview of the biomarker pipeline for TB detection at the point-of-care level, including for paediatric TB.

The presentations and audio are now available on the NDWG website as follows:

  • Agenda
  • Session I - Supporting TB elimination: Advances towards delivering new diagnostics for latent tuberculosis infection
  • Session II - Next Generation Sequencing for improved management of patients with drug resistant TB
  • Session III - Advancing biomarker discovery for TB point-of-care tests
  • NDWG launches consultation on draft TPP for a test of progression of LTBI

    The New Diagnostics Working Group and its Task Force on tests for progression of LTBI to active disease have recently launched an online consultation to gather input on a draft Target Product Profile (TPP) for a test of progression of latent tuberculosis infection (LTBI).

    Reactivation of LTBI is the source of the vast majority of new TB cases in low transmission areas. As global TB incidence declines, preventing progression from LTBI to active TB will be crucial for cutting transmission and reaching the goal of TB elimination. The introduction of targeted and cost-effective treatment of individuals with LTBI requires a diagnostic test to identify the small proportion of latently infected persons who will progress to active disease.

    A prognostic test for determining the risk of progression from LTBI to active disease is currently unavailable. To support the development of this new test, FIND has defined a draft TPP with contribution from the NDWG LTBI Task Force and other experts in the field. This document will provide guidance to diagnostic developers as to the key characteristics that the test needs to fulfill in order to meet requirements.

    The NDWG is conducting an online survey to gather input from a group of stakeholders representing researchers, endemic countries, governmental and non-governmental organizations, test developers and the patient community. Participants will have the opportunity to evaluate the key performance and operational characteristics as defined in the TPP in order to build large consensus. Results will be discussed by an expert group which will be convened by the NDWG Task Force on LTBI on July 1st 2016 in Milan, Italy, in order to finalize the TPP and submit the document to WHO for endorsement.

    More information about the NDWG Task Force on LTBI

    News Archive